Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
HIV Patients
100%
Efavirenz
100%
Neurocognitive Function
100%
Lopinavir
60%
Hepatitis C Virus
30%
HIV Viral Load
30%
Neurocognitive
20%
Hepatitis C Coinfection
20%
Information Processing Speed
20%
Cerebrospinal Fluid
10%
Multivariable
10%
Comorbidity
10%
Central Nervous System
10%
Neurotoxicity
10%
CD4+ T
10%
Serostatus
10%
Antiretroviral
10%
Randomized Clinical Trial
10%
Antiretroviral Therapy
10%
Executive Function
10%
HIV RNA
10%
Central Nervous System Toxicity
10%
Cognitive Ability
10%
Neurocognitive Testing
10%
Verbal Fluency
10%
Antiviral Drugs
10%
Psychosocial Outcomes
10%
Working Memory
10%
Second-line Therapy
10%
Effect Study
10%
Therapy Effect
10%
Antiretroviral Therapy Regimens
10%
HIV Antiretroviral Therapy
10%
Severely Ill Patients
10%
Observational Cohort
10%
Cohort-based
10%
Research Cohort
10%
Neurocognitive Complications
10%
Medicine and Dentistry
Human Immunodeficiency Virus
100%
Efavirenz
100%
Lopinavir/Ritonavir
60%
Hepatitis C Virus
50%
Antiretroviral Therapy
30%
Mixed Infection
20%
Cerebrospinal Fluid
10%
T-Helper Cell
10%
Clinician
10%
Central Nervous System
10%
Therapy Effect
10%
Neurotoxicity
10%
Cognitive Function
10%
Working Memory
10%
Central Nervous System Toxicity
10%
Comorbidity
10%
Randomized Clinical Trials
10%
Neuroscience
Human Immunodeficiency Virus
100%
Efavirenz
100%
Lopinavir/Ritonavir
60%
Hepatitis C Virus
50%
Information Processing
20%
Blood Plasma
20%
Central Nervous System
10%
Neurotoxicity
10%
T Cell
10%
Cognitive Function
10%
CD4
10%
Antiretroviral Drugs
10%
Central Nervous System Toxicity
10%
Comorbidity
10%
Working Memory
10%
Psychology
Information Processing
100%
Neurological System
100%
Comorbidity
50%
Cognitive Function
50%
Working Memory
50%
Cerebrospinal Fluid
50%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
100%
Efavirenz
100%
Lopinavir Plus Ritonavir
60%
Hepatitis C Virus
50%
Mixed Infection
20%
Neurotoxicity
10%
Randomized Clinical Trial
10%
Central Nervous System Toxicity
10%
Comorbidity
10%